Novo Nordisk CEO says CVS breakup has no material impact on the weight-loss drug giant

What happened: Novo Nordisk (NVO) CEO Mike Doustdar said CVS Health's (CVS) planned breakup has no material impact on the company, though it will now require two separate negotiations over product formularies. Key numbers: CVS plans to split its $117 billion healthcare empire into two standalone, publicly traded businesses. The breakup is slated to be completed in the first half of 2028. Why it matters: The separation reverses years of vertical integration and unwinds the 2018 acquisition of Aetna. Doustdar said selling popular products makes the dual negotiation process easier. Market: -12.8% today ($79.68), +1.1% YTD, 2.6x vol — as of 18:33 UTC Verified: Q3_2026 (Nov 4) EPS $2.09 vs $1.65 est, +26.6% beat; next print ~Feb 3

Novo Nordisk (NVO) CEO Mike Doustdar said CVS Health's (CVS) planned breakup has no material impact on the company, though it will now require two separate negotiations over product formularies.

The separation reverses years of vertical integration and unwinds the 2018 acquisition of Aetna. Doustdar said selling popular products makes the dual negotiation process easier. Market: -12.8% today ($79.68), +1.1% YTD, 2.6x vol — as of 18:33 UTC Verified: Q3_2026 (Nov 4) EPS $2.09 vs $1.65 est, +26.6% beat; next print ~Feb 3